BERLIN, NIMES, France and RICHMOND, California - Diagnostics company BRAHMS Aktiengesellschaft, Cezanne and Lumiphore Inc., a biotechnology leader from California, announced that they have signed an agreement on incorporation of Lumiphore’s Lumi4(R)-Tb complexes in BRAHMS diagnostic tests.
Under the agreement, BRAHMS together with its subsidiary Cezanne, developer and manufacturer of KRYPTOR automated diagnostic solutions, has the non-exclusive rights to incorporate Lumi4(R) technology into current and future diagnostic tests and the exclusive rights to use the technology in diagnostic tests for Down’s Syndrome including Trisomy 21, 13 and 18, Triploidy, Translocation, and Mosaicism.
“Lumiphore’s goal is to bring the benefits of lanthanide-based homogenous assays to the diagnostic markets, from central labs to point-of-care applications. Detection sensitivity and simplicity of use as well as material cost reductions in reagent use, labor, and reader platforms are all benefits of Lumiphore’s new reporter technology,” said Steve Blose Lumiphore’s Chief Business Officer.
“Using Lumi4(R)-Tb in the reader technology of our diagnostic tests will provide multiple benefit for BRAHMS. Thus we will take Lumi4(R)-Tb into consideration for the development of future analysis systems, both in laboratories and point-of-care-formats,” said Ansgar Schmitt, BRAHMS’ Vice President Business Development.
Lumi4(R)-Tb will both increase sensitivity of BRAHMS diagnostic tests and allow the development of multiplexed assays (measuring 3-4 parameters in one test sample).
About BRAHMS Aktiengesellschaft
The BRAHMS AG conducts researches, develops, produces and markets innovative diagnostic biomarkers. The company sells its products in more than 65 countries via its own subsidiary companies and sales organizations as well as laboratory systems from its own production and globally operating licensees.
About Lumiphore, Inc.
Based in Richmond, California, Lumiphore Inc, a privately held company, is a biotechnology leader in the development of proprietary fluorescent-metal lanthanide technology for use in high-value applications which are commercialized through market-specific alliances with corporate partners. Lumi4(R) complexes are a new class of fluorescent-metal lanthanide detection reagents based on technology patented by Professor Kenneth N. Raymond and coworkers at the University of California, Berkeley. Lumi4(R) is a registered mark of Lumiphore, Inc.
Media Contact BRAHMS Aktiengesellschaft Ingo Buchholzer Public Relations Manager +49-3302-883-637 i.buchholzer@brahms.de www.brahms.de Lumiphore, Inc. Stephen Blose Chief Business Officer +1-415-318-4457 mvsgroup@msn.com www.lumiphore.com Cezanne,SAS Emmanuel Bois President +33-466-365-236 ebois@cezanne.fr www.cezanne.fr
Source: BRAHMS Aktiengesellschaft
Media Contact: BRAHMS Aktiengesellschaft, Ingo Buchholzer, Public Relations Manager, +49-3302-883-637, i.buchholzer at brahms.de, http://www.brahms.de. Lumiphore, Inc., Stephen Blose, Chief Business Officer, +1-415-318-4457, mvsgroup at msn.com, http://www.lumiphore.com. Cezanne,SAS, Emmanuel Bois, President, +33-466-365-236, ebois at cezanne.fr, http://www.cezanne.fr
Related Press Releases
Media Invite: Citibank Partners With Virgin MegastoreSeptember 2nd, 2009 DUBAI - Citibank in partnership with Virgin Megastore invite you to join them on Thursday 3rd September 2009, when they will announce details about their strategic partnership to bring their products into Virgin Megastore and offer value-added discounts, access to exclusive events and many other exciting programs that Virgin Megastore and Citibank will be co-developing in the years to come. The press briefing takes place at Virgin Megastore - Mall of the Emirates at 2:00pm.
B-R-A-H-M-S and Thermo Fisher Scientific Join Forces to Create a Leader in Specialty DiagnosticsSeptember 2nd, 2009 HENNIGSDORF, Germany - B-R-A-H-M-S, a leading diagnostics company, and Thermo Fisher Scientific, the world leader in serving science, join forces to establish a European Center of Excellence for clinical diagnostics with a focus on innovative biomarkers. B-R-A-H-M-S announces the signature of a Share Purchase Agreement (SPA) with Thermo Fisher Scientific Inc.
BRAHMS KRYPTOR Compact is Certified by the Fetal Medicine Foundation (FMF)July 16th, 2009 HENNIGSDORF, Germany - The Fetal Medicine Foundation (FMF) confirmed that BRAHMS KRYPTOR compact is fulfilling the requirements for first trimester biochemical screening. Non-invasive biomarker tests together with the measurement of nuchal translucency (NT) allow the risk assessment of Down's syndrome without jeopardising the fetus.
Demand for Private Swine Flu Tests as Government Stops TestingJuly 15th, 2009 LONDON -
- MediChecks.com is the First Company in the UK to Make Available a Swine Flu Test to Individuals and Companies Nationally
The swine flu test which can be purchased online costs GBP125 is carried out on two swab samples and results are available with 2-3 days. The test kit is posted to the patient's home.
Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics MarketJune 22nd, 2009 LONDON - The European diabetes diagnostics market is poised for expansion with segments such as self-monitoring and point-of-care (POC) tests offering tremendous growth potential. Heightened efforts to generate awareness about diabetes and related diagnostic tests are a key driver in market development.
Agendia Supports Genentech's Citizen's Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory StandardsMay 27th, 2009 HUNTINGTON BEACH, California, and AMSTERDAM - Agendia, a world leader in molecular cancer diagnostics, today announced its strong support of Genentech's Citizen's Petition. Filed on December 5, 2008, Docket No.
Ipsogen Launches a New Test to Guide Hormonotherapy Prescription in Breast CancerMay 6th, 2009 MARSEILLE, France - The Genomic HR Test Will Help Pathologists to Identify Endocrine-Responsive Tumors That Should Benefit From Hormonotherapy
Ipsogen SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, manufacturing and commercialization of diagnostic assays for breast cancer and leukemia, today announces the European launch of the MapQuant Dx(TM) HR test. Running on an Affymetrix microarray diagnostic platform, this new genomic test will improve the identification of endocrine-responsive tumors by measuring the expression of genes related to oestrogen and progesterone biology in breast cancer.
Frost & Sullivan Award Reinforces Outstanding Product Line Strategy by SIRS-LabMay 6th, 2009 LONDON - The Frost & Sullivan "2009 European Molecular Diagnostics for Infectious Diseases Product Line Strategy of the Year Award", is presented to SIRS-Lab GmbH. The company's exceptional product line for sepsis diagnosis and monitoring make it a worthy recipient of this award.
AdvanDx Launches Fast, 90 Minutes Protocol for All CE-IVD Marked PNA FISH(R) Tests in EuropeApril 27th, 2009 WOBURN, Massachusetts and VEDBAEK, Denmark - Pathogen Identification Results in 90 Minutes Direct from Positive Blood Cultures
- Faster Results to Help Clinicians Improve Antibiotic Selection and Outcomes for Critical Infections
AdvanDx today announced that it has launched a fast, 90 minutes protocol for all CE-IVD marked PNA FISH(R) tests in Europe. The fast protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization time from 90 minutes to 30 minutes.
Chinese Government and Bill & Melinda Gates Foundation Announce Partnership to Fight TuberculosisMarch 31st, 2009 BEIJING - US$33 million Gates Foundation grant to help China introduce innovative TB control methods, reduce growing threat of drug-resistant TB
At a global meeting of health ministers today, Bill Gates joined Chinese Minister of Health Chen Zhu to announce an innovative partnership to help fight a serious tuberculosis epidemic in China. The initiative will be led by the Chinese Ministry of Health and is supported by a grant of US$33 million over five years from the Bill & Melinda Gates Foundation.
Related News
'NanoPen' may revolutionise electronics sector, medical diagnostic testsSeptember 3rd, 2009 WASHINGTON - A team of scientists in California have announced the creation of a 'NanoPen' that can simplify the method of laying down patterns of nanoparticles-from wires to circuits-for making futuristic electronic devices, medical diagnostic tests, and other much-anticipated nanotech applications. Writing about their work in ACS' Nano Letters, Ming Wu and colleagues point out that researchers have already developed several different techniques for producing patterns of nanoparticles, which are barely 1/50,000th the width of a human hair.
PM undergoes medical check-upJanuary 19th, 2009 NEW DELHI - Prime Minister Manmohan Singh Tuesday visited the All India Institute of Medical Sciences (AIIMS) for an overall medical check-up. Manmohan Singh is undergoing diagnostic tests that will be completed Wednesday, the Prime Minister's Office (PMO) said in a statement.
Rare sheep perfect blood donors for diagnosing infectious disease in developing worldJuly 4th, 2009 WASHINGTON - Scientists at the Stanford University School of Medicine say that the hair sheep, a less-hirsute version of the familiar woolly barnyard resident, may be key to better diagnostic tests in developing world. The researchers have found that not only are these ruminants low-maintenance and parasite-resistant, they're also perfect blood donors for the microbiology tests necessary to diagnose infectious disease in the developing world.
Quality control norms a must for all diagnostic labsSeptember 10th, 2009 Kolkata, Sept 10 (IBNS) Bio-Rad Laboratories in association with Quality Council of India (QCI), Government of India, organized a seminar on quality control (QC) in diagnostic laboratories Wednesday. The seminar focused on the need for upgrading and enforcing QC practices in laboratories all over the country.
China develops new method to test swine flu in pigsMay 4th, 2009 BEIJING - China has developed a new diagnostic method to test influenza A(H1N1) virus in pigs, the agriculture ministry said. Officials said the new method can deliver test results within five hours.
Ocimum Biosolutions to introduce new test for H1N1 fluMay 4th, 2009 HYDERABAD - Ocimum Biosolutions announced the launch of a microarray-based test (research use only) for the latest version of the H1N1 flu. The company reported that it updated its custom chip probes using sequence information from the latest strain of the swine flu from the NCBI site.
'Gifted children also need nurturing and support'January 16th, 2009 WASHINGTON - 'Oh, they're smart, they'll do fine on their own', is what is often said about gifted children, but according to experts they require just as much attention and support as other students with physical, behavioural and emotional needs to thrive at school. Steven I. Pfeiffer, a professor at the Florida State University department of educational psychology, works with gifted children and their families in counselling and has been recognised as a leading authority on the subject.
Novel TB test may provide results quickly, efficientlyMay 8th, 2009 WASHINGTON - A scientist has developed a new diagnostic test for TB, called Xpert MTB/RIF, which can provide results quickly and efficiently. The test, developed by Dr.
Tangible results during Manmohan's US visit, says envoyAugust 12th, 2009 NEW DELHI - Setting the tone for Prime Minister Manmohan Singh's official visit to Washington in November, US ambassador to India Timothy J. Roemer Wednesday said the "most tangible results of the partnership" would be announced during the trip.
Harvard scientist fashions cheap, easy-to-use diagnostic testFebruary 22nd, 2009 WASHINGTON - A Harvard scientist has developed a versatile and low cost test that can detect infectious or chronic diseases with only a tiny sample of urine or blood. George Whitesides, a Harvard University professor, is coupling advanced microfluidics with one of humankind's oldest technologies - paper.
